PT  - JOURNAL ARTICLE
AU  - De-la-Rosa-Martinez, Daniel
AU  - Delaye-Martínez, Marco Antonio
AU  - Bello-Chavolla, Omar Yaxmehen
AU  - Sicilia-Andrade, Alejandro
AU  - Juárez-Cruz, Isaac David
AU  - Fermín-Martínez, Carlos A.
AU  - Márquez-Salinas, Alejandro
AU  - Cañedo-Guerra, Enrique
AU  - Fernández-Chirino, Luisa
AU  - Martínez-Gutiérrez, Mónica
AU  - Sandoval-Colin, Daniel Eduardo
AU  - Vilar-Compte, Diana
TI  - Long-term manifestations and modifiers of prevalence estimates of the post-COVID-19 syndrome: A systematic review and meta-analysis
AID  - 10.1101/2021.10.17.21265123
DP  - 2021 Jan 01
TA  - medRxiv
PG  - 2021.10.17.21265123
4099  - http://medrxiv.org/content/early/2021/10/18/2021.10.17.21265123.short
4100  - http://medrxiv.org/content/early/2021/10/18/2021.10.17.21265123.full
AB  - Background Post-acute COVID-19 syndrome (PACS) is a multi-system disease comprising persistent symptomatology after the acute phase of infection. Long-term PACS effects significantly impact patient outcomes, but their incidence remains uncharacterized due to high heterogeneity between studies. Therefore, we aimed to summarize published data on PACS, characterizing the clinical presentation, prevalence, and modifiers of prevalence estimates.Method In this systematic review and meta-analysis, we research MEDLINE for original studies published from January 1st, 2020, to January 31st, 2021, that reported proportions of PACS manifestations. Studies were eligible for inclusion if they included patients aged ≥18 years with confirmed COVID-19 by RT-PCR or antigen testing and a minimum follow-up of 21 days. The prevalence of individual manifestations across studies was pooled using random-effects meta-analysis. For evaluating determinants of heterogeneity, meta-regression analysis was performed. This study was registered in PROSPERO (CRD42019125025).Results After screening 1,235 studies, we included 29 reports for analysis. Twenty-seven meta-analyses were performed, and 61 long-term manifestations were described. The pooled prevalence of PACS was 56% (95%CI 45-66%), with the most common manifestations being diminished health status, fatigue, asthenia, dyspnea, myalgias, hyposmia and dysgeusia. Most of the included studies presented high heterogeneity. After conducting the meta-regression analysis, we identified that age, gender, number of comorbidities, and reported symptoms significantly modify the prevalence estimation of PACS long-term manifestations.Conclusion PACS is inconsistently reported between studies, and population characteristics influence the prevalence estimates due to high heterogeneity. A systematized approach for the study of PACS is needed to characterize its impact adequately.Funding noneCompeting Interest StatementThe authors have declared no competing interest.Funding StatementNo specific funding was received for this studyAuthor DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:N/AI confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesData is fully available within the manuscript